Frazier Life Sciences Management, L.P.
Q4 2022 13F-HR/A Holdings
Net value change ($000)
+309,731
(23.8%)
New positions
6
Sold out positions
6
Turnover %
12.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| NAMS | 101,823 | NEW |
| Imago BioSciences, Inc. | 98,622 | 220.5% |
| VRNA | 52,118 | 242.9% |
| CHINOOK THERAPEUTICS, INC. | 29,993 | 35.8% |
| PCVX | 29,868 | 80.4% |
| SNDX | 12,380 | 15.1% |
| VectivBio Holding AG | 11,481 | NEW |
| REPL | 11,414 | 82.0% |
| RNAM | 11,095 | NEW |
| Allakos Inc. | 11,022 | 37.6% |
Top Reduces (Value $000, Stocks/ETFs)
| ARQT | -37,429 | -22.6% |
| Tricida, Inc. | -26,721 | -100.0% |
| FRAZIER LIFESCIENCES ACQU CO | -15,235 | -100.0% |
| Gracell Biotechnologies Inc. | -9,306 | -100.0% |
| COGT | -6,564 | -21.2% |
| MIRM | -5,150 | -6.4% |
| TARS | -4,397 | -14.4% |
| NTLA | -4,291 | -37.6% |
| HilleVax, Inc. | -3,513 | -2.1% |
| Merus N.V. | -3,404 | -22.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|